OncoMatch/Clinical Trials/NCT04795882
A New Study Evaluating the Activity of Modular CAR T for mYeloma
Is NCT04795882 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies multiple treatments including BCMA CAR T cells and BCMA/CD19 CAR T cells for multiple myeloma.
Treatment: BCMA CAR T cells · BCMA/CD19 CAR T cells — This is a Phase 1 rolling 6 trial design evaluating safety of a novel BCMA Chimeric Antigen Receptor (CAR) alone and of CAR T cells engineered to co-express BCMA CAR and a CD19 CAR in patients with relapsed / refractory Multiple Myeloma. The study will assess the feasibility of generating these Advanced Therapy Investigational Products (ATIMPs) and the safety of administering the CAR T cells (either BCMA alone or co-expressed with CD19) in patients with relapsed / refractory multiple myeloma.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Multiple Myeloma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: proteasome inhibitor
≥3 prior lines of therapies (including proteasome inhibitor, IMiD, anti CD38 antibody)
Must have received: IMiD
≥3 prior lines of therapies (including proteasome inhibitor, IMiD, anti CD38 antibody)
Must have received: anti-CD38 antibody
≥3 prior lines of therapies (including proteasome inhibitor, IMiD, anti CD38 antibody)
Cannot have received: gene therapy
Prior treatment with investigational or approved gene therapy or cell therapy products
Cannot have received: cell therapy
Prior treatment with investigational or approved gene therapy or cell therapy products
Lab requirements
Blood counts
Absolute Neutrophil Count (ANC)≥1x10^9/L, Platelets (plt)≥50x10^9/L, Haemoglobin (Hb)≥80 /L, lymphocyte count ≥0.3x10^9/L
Kidney function
Creatinine Clearance (CrCl)≥40ml/min; Chronic renal impairment requiring dialysis [excluded]
Liver function
alanine aminotransferase or aspartate aminotransferase ≥3x upper limit normal (ULN), or total bilirubin ≥25umol/L (1.5mg/dL), except in patients with Gilbert's syndrome, or evidence of end-stage liver disease (e.g. ascites, hepatic encephalopathy)
Cardiac function
Left ventricular ejection fraction < 50% (ECHO or MUGA) [excluded]; Corrected QT interval (QTc)>470 ms on ECG [excluded]; Uncontrolled cardiac arrhythmia (patients with rate-controlled atrial fibrillation are not excluded); Oxygen saturation ≤ 90% on air [excluded]
Creatinine Clearance (CrCl)≥40ml/min, Absolute Neutrophil Count (ANC)≥1x10^9/L, Platelets (plt)≥50x10^9/L, Haemoglobin (Hb)≥80 /L, lymphocyte count ≥0.3x10^9/L; alanine aminotransferase or aspartate aminotransferase ≥3x upper limit normal (ULN), or total bilirubin ≥25umol/L (1.5mg/dL), except in patients with Gilbert's syndrome, or evidence of end-stage liver disease (e.g. ascites, hepatic encephalopathy); Left ventricular ejection fraction < 50% (ECHO or MUGA); Corrected QT interval (QTc)>470 ms on ECG; Oxygen saturation ≤ 90% on air
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT04795882 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior gene therapy, cell therapy disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages